At what pace is the her2 inhibitors market growing, and what is its estimated value?
The HER2 inhibitors market size has grown strongly in recent years. It will grow from $8.77 billion in 2024 to $9.64 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to biotechnological advances, clinical trial success, shift in treatment paradigm, research and development investments, patient outcomes improvement.
The HER2 inhibitors market size is expected to see strong growth in the next few years. It will grow to $13.61 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to patient-centric care models, regulatory changes and approvals, drug resistance management, global market penetration, expanded indications, precision oncology adoption. Major trends in the forecast period include patient advocacy and awareness, clinical trials and research, early detection and diagnosis, precision medicine and biomarker testing, adjuvant and neoadjuvant therapy.
Get Your Free Sample of The Global HER2 Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3396&type=smp
What are the top drivers to the rising demand in the her2 inhibitors market?
The rise in the number of breast cancer cases across the globe is likely to contribute to the growth of the HER-2 inhibitors market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in the breast cancer incidence rate globally is anticipated to boost the demand for the HER-2 inhibitors market over the forthcoming years.
How is the her2 inhibitors market segmented?
The HER2 inhibitors market covered in this report is segmented –
1) By Treatment: Monotherapy, Combination Therapy
2) By Application: Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer, Other Applications
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Monotherapy: Single-Agent HER2 Inhibitors, Targeted HER2 Therapies
2) By Combination Therapy: HER2 Inhibitors Combined With Chemotherapy, HER2 Inhibitors Combined With Targeted Therapies, HER2 Inhibitors Combined With Hormonal Therapies
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report
Who are the top competitors in the her2 inhibitors market?
Major companies operating in the HER2 inhibitors market include Pfizer Inc., Johnson & Johnson Services Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly International Corp., C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Catalent Inc., Ipsen SA, the Pierre Fabre Group, Biocon Biopharmaceuticals Pvt. Ltd., Innovent Biologics Inc., Halozyme Therapeutics Inc., Seattle Genetics Inc., Zymeworks Inc., Puma Biotechnology Inc., MacroGenics Inc., Mersana Therapeutics Inc., Cellestia Biotech AG
How will emerging trends drive the her2 inhibitors market throughout the forecast period?
Major companies operating in the HER2 inhibitor market are focused on developing treatments for HER2-low breast cancer to gain a competitive edge in the market. HER2-low breast cancer is a newly defined subset of HER2-negative breast cancer, which includes tumors that do not overexpress or make too many copies of the HER2 protein. For instance, in August 2022, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, the U.S. Food and Drug Administration (FDA) approved Enhertu (fam-trastuzumab deruxtecan-nxki) as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer. Enhertu is prescribed via intravenous infusion to address HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer in adults who have undergone prior metastatic chemotherapy or experienced disease recurrence within six months of completing adjuvant chemotherapy.
Which regional trends are influencing the her2 inhibitors market, and which area dominates the industry?
North America was the largest region in the HER2 inhibitors market in 2024. Middle East is expected to be the fastest-growing region in the HER2 inhibitors market report during the forecast period. The regions covered in the her2 inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The HER2 Inhibitors Market Report 2025 Offer?
The her2 inhibitors market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
HER2 inhibitors refer to a group of drugs used to treat certain HER2-low breast malignancies as well as all stages of HER2-positive breast cancer, from early-stage to metastatic. Anti-HER2 drugs bind to the HER2 receptor proteins on the surface of breast cancer cells, and they function by preventing the HER2 receptors in HER2-positive breast cancer from receiving growth impulses.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3396
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
